Cell and gene therapies (CGT) represent a revolution in medicine, and give hope to many cancer patients with no alternatives. However, producing these treatments is currently so complex and expensive that many will not benefit from them. Our vision is to make CGT manufacturing simple, safe and reproducible with a self-contained automated bioreactor. Our patented platform technology allows clinicians to control their own supply, providing affordable personalised treatments on demand.
